Why Aldeyra Therapeutics, Inc.’s (ALDX) Stock Is Down 7.70%
As of Wednesday, October 14, Aldeyra Therapeutics, Inc.’s ALDX share price has dipped by 7.70%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Commentary & Analysis
Why Aldeyra Therapeutics, Inc.’s (ALDX) Stock Is Down 11.07%
As of Wednesday, October 14, Aldeyra Therapeutics, Inc.’s ALDX share price has dipped by 11.07%, which has investors questioning if this is right time to buy.Tudor Pop
Why Aldeyra Therapeutics, Inc.’s (ALDX) Stock Is Up 5.93%
As of Tuesday, October 06, Aldeyra Therapeutics, Inc.’s ALDX share price has surged by 5.93%, which has investors questioning if this is right time to sell.Michael Rose
Why Aldeyra Therapeutics, Inc.’s (ALDX) Stock Is Down 10.10%
As of Monday, October 05, Aldeyra Therapeutics, Inc.’s ALDX share price has dipped by 10.10%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Aldeyra Therapeutics, Inc.’s (ALDX) Stock Is Down 17.20%
As of Monday, October 05, Aldeyra Therapeutics, Inc.’s ALDX share price has dipped by 17.20%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | ALDX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $42.2 | $208.8 | 15% |
|
| Shares Out (Mil) | 60.3 | 53.9 | 52% |
|
| Institutional Ownership | 92.7% | 93.1% | 62% |
|
| Float (Mil) | 48.9 | 41.4 | 46% |
|
| Beta | 1.20 | 0.95 | 70% |
|
| Avg Daily Volume (000s) | 2,585 | 614 | 85% |
|
| Price Change (52-week) |
(87.6%) | 45.3% | 6% |
|
| Growth | ALDX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.8% | na |
|
| Net Income (5yr) | 2.1% | (10.2%) | 43% |
|
| EPS (5yr) | 12.6% | 15.7% | 52 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (23.3%) | (15.7%) | 28% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 4 | 4 | |
| Current EPS | ($0.093) | ($0.340) | ($0.275) | |
| Month Ago EPS | ($0.093) | ($0.340) | ($0.275) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.070) | ($0.300) | ($0.200) | |
| Year/Year Chg | 3.3% | (39.7%) | (74.3%) | |
| Financials | ALDX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($23) | ($44) | 23% |
|
| EPS (TTM) | ($0.383) | ($1.600) | 29% |
|
| Operating Cash Flow (TTM) (Mil) | ($22) | ($33) | 14% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $47 | $174 | 15% |
|
| Valuation | ALDX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.11 | 2.09 | 29% |
|
| P/E | na | 19.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | ALDX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.0% | na |
|
| Net Margin | na | (75.3%) | na |
|
| ROA | (34.8%) | (47.2%) | 15% |
|
| ROE | (49.5%) | (54.2%) | 15% |
|
| Liabilities to Assets | 20.3% | 29.1% | 13% |
|
| F-Score | 4 | 2 | 33% |
|
Aldeyra Therapeutics, Inc. did not pass any screens on 10/16/2026.
